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Summary
Patient adherence is a key consideration in the choice of a topical regimen for the 
treatment of onychomycosis. The objective of this study was to investigate patient- 
reported outcomes (treatment utilisation, adherence and satisfaction) in onychomyco-
sis treated with once- weekly amorolfine 5% nail lacquer versus once- daily ciclopirox 
8% nail lacquer (Study A) or once- daily urea 40% ointment/bifonazole 1% cream com-
bination regimen (Study B). Study A: Subjects received amorolfine and ciclopirox on 
opposite feet for 12 weeks. Study B: Subjects received amorolfine and urea/bifona-
zole on opposite feet for 6- 7 weeks. Assessments included subject adherence as per 
label, treatment preference and questionnaire. Study A: More subjects adhered to 
amorolfine (85%) than to ciclopirox (60%) (P = .025). Overall, subjects were satisfied 
(95% vs 100%, respectively) and the treatments were balanced in terms of preference 
(50% vs 45%) at week 12. Study B: More subjects adhered to amorolfine dosage 
(81.8%) than to the dosage of the urea/bifonazole combination regimen (59.1%) 
(P = .096). At the end of study, 85.7% of subjects preferred amorolfine versus 14.3% 
for urea/bifonazole. Fewer subjects experienced local side effects with amorolfine 
(4.5%) compared to urea (27.3%) and bifonazole (15%). Amorolfine 5% nail lacquer 
offers a simple and convenient treatment option, which may result in improved patient 
adherence and consequently lead to improved efficacy and patient satisfaction.
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1  | INTRODUCTION
Onychomycosis is a fungal infection of fingernails and toenails which 
may have a marked effect on patient quality of life.1,2 It is the most 
prevalent nail disease accounting for up to 50% of all onychopa-
thies.3 According to population- based studies, the mean prevalence 
of onychomycosis in the general population in Europe and North 
America is 4.3% (95% confidence interval [CI]: 1.9- 6.8).4 Toenails are 
involved in the majority of cases due to the slow growth and increased 
exposure to injury, facilitating the establishment of fungal infection.5 
Dermatophytes are responsible for most cases (65%) of onychomy-
coses.4 There are several variants of onychomycosis described in the 
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literature, with distal and lateral subungual onychomycosis (DLSO) 
being the most frequent variation.6,7 Onychomycosis is characterised 
by evident changes to the nail such as dyspigmentation, onycholysis 
and nail plate thickening. These changes result in substantial embar-
rassment for the patient, which deters many from consulting a phy-
sician until the disease progresses to more severe states or impairs 
daily life.8-10
The availability of non- prescription topical antifungal agents facil-
itates the use of effective and well- tolerated treatments in the early 
stages of fungal nail infection. Amorolfine 5% nail lacquer, ciclopirox 
8% nail lacquer, urea 40% ointment and bifonazole 1% cream are avail-
able over the counter (OTC) worldwide. Adherence to treatment is the 
process by which patients take their medications as prescribed (or rec-
ommended in the label).11 Adherence to topical antifungal therapy for 
the treatment of onychomycosis has a major influence on outcome.12 
A Chinese study showed that the cure rate of onychomycosis in pa-
tients with good adherence was 63% (58/92), whereas in non- adherent 
patients this rate was merely 2% (6/293).12 Several adherence studies 
in chronic dermatoses such as psoriasis, atopic dermatitis or rosacea 
have shown that ensuring a good adherence to topical therapy is as 
important as reaching the correct diagnosis and selecting the appropri-
ate treatment.13-17 Treatment of toenail onychomycosis may require a 
lengthy course of therapy and thus, patient adherence is a key consider-
ation in the choice of a topical regimen. Patient adherence to long- term 
topical treatment may depend not only on the efficacy of the treatment 
but also on the ease of use, application procedure and tolerance. Such 
factors include inconvenient or time- consuming application of medica-
tion, ambiguous/complicated usage instructions or side effects such as 
irritation, burning and dryness.18,19 These subjective factors are infre-
quently assessed in prospective randomised studies.
Mild- to- moderate onychomycosis can be effectively and safely 
treated with topical antifungals, a number of which can be purchased 
OTC with the advice of pharmacists.20 Hence, with self- treatment, 
convenience of use is essential to avoid discouragement or inappro-
priate treatment application.
Amorolfine 5% nail lacquer (Loceryl® 5% Nail Lacquer; Galderma, 
Lausanne, Switzerland) is a broad- spectrum topical antimycotic, in-
dicated for the treatment of onychomycosis without matrix involve-
ment. The advantage of this agent is the persistent antifungal effect 
on the nail bed, allowing a once- weekly application as recommended 
in the product label. Filing of the nail plate is performed, prior to appli-
cation, to increase the penetration of amorolfine to the nail bed, where 
most fungi reside.21-25
Ciclopirox 8% (Ciclopoli® Nail Lacquer; Taurus Pharma, Bad 
Homburg, Germany) is another broad- spectrum topical antimycotic 
which, according to the label recommendation, must be applied daily. 
No filing is recommended for this treatment.
The combination regimen of urea 40% ointment and bifonazole 
1% cream (Canesten® Fungal Nail Treatment Set; Bayer, Pymble, 
Australia) provides chemical nail ablation followed by topical antifun-
gal treatment. Urea 40% ointment under occlusion possesses kerato-
lytic properties and is indicated for the softening and removal of the 
diseased/dystrophic nails in onychomycosis.26,27 Bifonazole 1% cream 
is a broad- spectrum imidazole with antifungal activity, rubbed into the 
nail bed after nail debridement.28 According to the label recommen-
dation, the urea/bifonazole regimen must be applied on a daily basis. 
The duration of treatment is 6- 7 weeks and comprises two phases: 
2- 3 weeks for debridement of the affected nail with the urea 40% 
ointment followed by 4 weeks of antifungal treatment with bifonazole 
1%.29
These currently available OTC topical antifungals offer different 
treatment modalities including daily or weekly application, or removal 
of the diseased nail.
The objective of the two randomised comparative clinical studies 
presented in this article was to investigate the influence of these dif-
ferent treatment modalities on patient- reported outcomes (treatment 
utilisation, adherence and satisfaction) in DLSO treated with once- 
weekly amorolfine versus once- daily ciclopirox (Study A) or once- daily 
urea/bifonazole (Study B).
2  | SUBJECTS AND METHODS
2.1 | Study design
The studies were conducted in accordance with the principles of the 
Declaration of Helsinki and Good Clinical Practices, and in compliance 
with local regulatory requirements. They were approved by institu-
tional review boards, and all subjects provided written informed con-
sent prior to study procedures.
2.1.1 | Study A (amorolfine 5% vs ciclopirox 8%)
This was a single- centre, randomised, investigator blinded, active con-
trolled, intra- individual, Phase IV study. The study involved subjects 
aged 18 years or older with a mycologically confirmed DLSO, and less 
than 80% of the nail surface area involved on at least one toenail of 
each foot, without matrix involvement.
Subjects were randomised on a 1:1 ratio to receive once- weekly 
amorolfine nail lacquer (after nail filing) for 12 weeks on the affected 
toenails of one foot and ciclopirox nail lacquer once daily for the same 
duration on the opposite foot after nail preparation. Prior to each ap-
plication of amorolfine nail lacquer on the nail plate, subjects were re-
quired to remove any former varnish layers with a nail varnish remover 
and subsequently file the surface of the nail (particularly the affected 
area) as thoroughly as possible. Ciclopirox nail lacquer was applied to 
the entire nail plate and surrounding skin of affected toenails, after 
removing the free toenail edge and diseased toenail with a nail clip-
per, if necessary. This study comprised visits at screening, baseline and 
weeks 4, 8 and 12.
2.1.2 | Study B (amorolfine 5% vs urea 40%/
bifonazole 1%)
This was a single- centre, randomised, open- label, active controlled, 
intra- individual, Phase IV study. The study involved subjects aged 
18 years or older with mycologically confirmed DLSO affecting no 
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more than 50% of the surface (from the nail edge) of at least one great 
toenail of each foot, without matrix involvement.
Subjects were randomised on a 1:1 ratio to receive amorolfine 
nail lacquer once weekly for a maximum of 7 weeks on the affected 
toenails of one foot and urea/bifonazole combination regimen, for the 
same duration on the opposite foot. Subjects in the latter group re-
ceived urea 40% ointment under occlusion, daily for the first 2- 3 weeks 
(phase I: removal of diseased nail). The procedure consisted of soaking 
the foot for 10 minutes in warm water, and subsequently removing 
the softened infected nail using a plastic nail scraper and applying the 
ointment on the nail prior to occlusion under a plaster. Following the 
removal of the diseased nail plate, the treatment consisted of daily 
bifonazole 1% cream application for the remaining 4 weeks (phase II: 
treatment of infection).
This study included visits at screening, baseline and weeks 2, 3 and 
6 or 7, depending on the duration of phase I.
2.2 | Assessments
2.2.1 | Study A
• Subject adherence to study treatments as per label (Summary of 
Product Characteristics [SmPC]) via completed subject diary: 
o Adherence rate as per label: Percentage of subjects “in and off 
label”.
o Non-adherence count as per label: number of “off label” 
episodes.
• Subject preference for study treatment at each postbaseline visit.
• Subject questionnaire at last visit.
• Incidence of adverse events (AEs) throughout the study.
2.2.2 | Study B
• Subject adherence with study treatments as per label (SmPC) via 
completed subject diary: 
o Adherence rate as per label: Percentage of subjects “in and off 
label”.
o Non-adherence count as per label: number of “off label” 
episodes.
• Subject preference at the end of phase I (week 2 or 3) and phase II 
(week 7 or early termination).
• Subject questionnaire at the end of each phase: 
o Phase I: At week 2 if complete removal of diseased nail plate 
was achieved, or at week 3 if continued application of urea was 
required for one additional week.
o Phase II: At week 7/early termination.
• Urea/bifonazole procedure performance: 
o Assessment of diseased toenail plate removal success rate by 
subjects and the investigator.
• Incidence of AEs throughout the study.
2.3 | Randomisation and sample size
For both studies, randomisation lists were generated by a statistician 
and transmitted to the assigned clinical packaging organisation for 
labelling. The RANUNI routine of the Statistical Analysis System (SAS 
Institute Inc., Cary, NC, USA) was used for the randomisation lists.
The randomisation lists and electronic files were secured in a 
locked cabinet with restricted access to only the designated per-
sonnel directly responsible for labelling and handling the study 
treatments.
No statistical rationale of sample size was necessary for these 
studies, as no inferential statistics were performed.
2.4 | Statistical analysis
Categorical variables, quantitative variables and subject’s 
 preference for treatment were analyzed using the McNemar test, 
paired Wilcoxon signed- rank test and sign test, respectively. The 
.05  probability level was chosen to declare significance. 
Demographic data, baseline characteristics and safety data were 
descriptively summarised. No missing values were replaced (ob-
served data only).
3  | RESULTS
3.1 | Subject disposition
Subject disposition of both studies is presented in Figure 1.
3.1.1 | Study A
The study was conducted at one centre in Tübingen, Germany from 
September 2015 to June 2016. A total of 20 subjects with a mean 
age of 54.5 years were enrolled and all of them completed the study. 
Subjects had a mean of 1.9 affected toenails per foot (Table 1).
F IGURE  1 Subject disposition
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3.1.2 | Study B
The study was conducted at one centre in Reykjavik, Iceland, from 
January 2016 to September 2016. A total of 22 subjects with a 
mean age of 55.3 years were enrolled. Of those, 20 subjects (90.9%) 
completed the study. Two subjects discontinued the study by re-
quest. Overall, subjects had a mean of 3.2 affected toenails per foot 
(Table 1).
3.2 | Patient- reported outcomes
3.2.1 | Study A
Subject adherence as per label: In the intent- to- treat (ITT) population, 
significantly more subjects adhered to the respective label with amo-
rolfine (85%) than with ciclopirox (60%) (P = .025) (Figure 2A). One 
subject in the amorolfine group missed 2 applications versus 8 subjects 
in the ciclopirox group with a mean of 3 missed applications (P = .008).
The reason for missing the application of amorolfine, as reported 
by the subject, was “forgot to use the treatment”. Subjects who 
missed applications of ciclopirox reported they “forgot to use the 
treatment” (5 subjects, 62.5%), “were away from home” (5 subjects, 
62.5%) and “did not have time to apply the treatment” (1 subject, 
12.5%).
In terms of overall preference, at week 12 the two treatments were 
balanced (50% vs 45%, respectively) without statistically significant 
difference at weeks 4, 8 or 12 (Figure 3A).
Based on the satisfaction questionnaire at the end of the 
study, subjects reported that for the treatment of an average of 
two nails per foot, amorolfine took longer to apply compared to ci-
clopirox (5.1 vs 2.6 minutes per application, respectively; P < .001). 
However, the total application time per week was approximately 
3.5- fold longer for ciclopirox than for amorolfine (18.2 vs 5.1 min-
utes). There was no statistically significant difference between 
treatments with respect to satisfaction with the frequency of ap-
plication (55% vs 40% very satisfied with amorolfine and ciclopirox 
respectively) (Figure 4A) and ease of use (45% per group found 
the treatment very easy to use) (Figure 4B). Subjects were over-
all satisfied with both amorolfine and ciclopirox (95% vs 100%, 
respectively) (Figure 4C). Ninety per cent of subjects considered 
continuing the use of amorolfine compared to 75% of subjects for 
ciclopirox. Approximately 80% of subjects stated they would rec-
ommend both products to family or friends.
3.2.2 | Study B
Subject adherence as per label: More subjects were adherent as per 
label with amorolfine than with the urea/bifonazole regimen (81.8% 
vs 59.1%, respectively, P = .096) (Figure 2B). One subject in the amo-
rolfine group missed a single application, whereas 3 subjects overused 
F IGURE  2 Subject adherence as per label for (A) Study A and (B) 
Study B (intent- to- treat population)
(A)
(B)
TABLE  1 Demographics and baseline disease characteristics 
(intent- to- treat population)
Study A 
Total 
(N = 20)
Study B 
Total 
(N = 22)
Age (years) N 20 22
Mean±SD 54.5 ± 8.7 55.3 ± 12.6
Min~Max 30~72 31~79
Gender N 20 22
Female 10 (50%) 5 (22.7%)
Male 10 (50%) 17 (77.3%)
Race N 20 22
Caucasian 20 (100%) 22 (100%)
Skin phototype N 20 22
I - 1 (4.5%)
II 20 (100%) 4 (18.2%)
III - 14 (63.6%)
IV - 3 (13.6%)
Number of affected 
nails
Mean±SD 1.9 ± 1.4 3.2 ± 1.7
Direct microscopic 
examination
Positive 20 (100%) 22 (100.0%)
Culture Positive 20 (100%) 22 (100.0%)
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the product. In the urea/bifonazole group, 9 subjects missed a mean 
of 2 applications (between 1 and 4). In non- adherent subjects, the 
mean number of missed applications was significantly higher for urea/
bifonazole than for amorolfine (P = .008).
The reason for missing the application of amorolfine was a non- 
related AE (accident). Most common reasons for missing the applica-
tion of urea included “being away from home” (44.4%), “did not have 
time to apply” (33.3%), “forgot to use” (22.2%), “tired of applying” 
(22.2%), “procedure too difficult to follow” (22.2%), and “local toler-
ance” (11.1%). For bifonazole, the most common reasons for missing 
applications included “forgot to use” (33.3%), “being away from home” 
(33.3%), “did not have time to apply” (11.1%) and “tired of applying” 
(11.1%).
Subject adherence in terms of nail preparation procedure: More 
subjects adhered to the nail preparation procedure for amorolfine (nail 
filing) than for urea/bifonazole (nail debridement) (86.4% vs 22.7%, 
respectively, P < .001). Significantly more “off label” episodes, in terms 
of nail preparation, were reported for urea/bifonazole (17 subjects 
with a mean of 3 episodes) than for amorolfine (3 subjects with a mean 
of 1 episode) (P < .001).
Urea/bifonazole procedure performance: At the end of the 
urea treatment (week 3), of 65 treated nails, 25 (38.5%) had been 
incompletely removed and the residual diseased toenails needed to be 
removed by the investigator.
In terms of subject overall preference, at the end of phase I, 90% 
preferred amorolfine and 10% preferred urea. At the end of phase II, 
the vast majority of subjects (85.7%) preferred amorolfine and 14.3% 
preferred bifonazole (Figure 3B).
The subject questionnaire at the end of the study phases showed 
that, over the course of a week, the application of amorolfine took 
significantly less time compared to nail debridement with urea during 
phase I (12.4 min/week vs 156.1 min/week, respectively, P < .001), 
and daily applications of bifonazole during phase II (10.3 min/day and 
week vs 7.6 min/day and 53.2 min/week, respectively). Nearly all sub-
jects were satisfied/very satisfied with the frequency of amorolfine 
applications compared to those of urea during phase I and bifonazole 
during phase II of the treatment (95.4% vs 54.6% and 95% vs 70%, 
respectively) (Figure 4D). Overall, more subjects found the application 
of amorolfine easy/very easy compared to that of urea and bifonazole 
(95.5% vs 45.5% during phase I and 95% vs 75% during phase II) 
(Figure 4E). Subjects were overall satisfied/very satisfied with the use 
of amorolfine vs urea, and vs bifonazole (90.9% vs 81.8% during phase 
I, 100% vs 90% during phase II, respectively) (Figure 4F). Fewer sub-
jects experienced local side effects with amorolfine (1 subject, 4.5% 
during phase I; 1 subject, 5% during phase II) compared to urea (6 
subjects, 27.3% during phase I) and bifonazole (3 subjects, 15% during 
phase II) (Figure 4G).
At the end of the study, nearly all subjects would recommend 
the use of both amorolfine and urea/bifonazole (100% vs 89.5%, re-
spectively). At end of study, all subjects (100%) considered to use 
amorolfine for 7- 10 additional months compared to 85% for urea/
bifonazole.
3.3 | Safety
None of the AEs reported in these studies, other than expected local 
reactions, were considered to be treatment related and none led to 
treatment discontinuation. All AEs were mild to moderate in severity.
4  | DISCUSSION
Good adherence to appropriate therapy remains critically impor-
tant for the prevention of treatment failure, disease progression 
and treatment escalation in dermatology.30 The two Phase IV stud-
ies discussed in this article investigated patient- reported outcomes 
(utilisation, adherence and satisfaction) following treatment with 
OTC topical antifungal agents: once- weekly amorolfine versus once- 
daily ciclopirox (Study A) or once- daily urea/bifonazole (Study B) in 
patients treated for DLSO. The three treatments compared in this 
study can be purchased OTC and need to be patient friendly to en-
sure good adherence.
In Study A (amorolfine vs ciclopirox), more subjects adhered to the 
instructions for use as per label for amorolfine than for ciclopirox. The 
main reasons for non- application of study treatments were that the 
F IGURE  3 Subject overall preference for (A) Study A and (B) 
Study B (intent- to- treat population)
(A)
(B)
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subjects forgot to use the treatments or that they were away from 
home. Subjects had no preference for either of the study treatments, 
although more subjects considered continuing to use amorolfine 
rather than ciclopirox after 12 weeks of use.
According to the questionnaire at last visit, subjects reported that 
amorolfine nail lacquer after filing took longer to apply than ciclopirox 
nail lacquer (without filing) (P < .001) and was less easy to spread 
(P = .008). Although the application procedure for amorolfine is slightly 
longer than for ciclopirox, it is carried out once weekly, whereas the 
procedure for ciclopirox must be carried out once daily. There was no 
statistically significant difference, over this 12- week study period, be-
tween treatments regarding satisfaction with the frequency of appli-
cation and ease of use.
The results of Study B (amorolfine vs urea vs bifonazole) indicated 
that subject adherence was better for amorolfine compared to urea/
bifonazole. More subjects preferred amorolfine compared to urea/bi-
fonazole. In addition, more subjects were satisfied with the frequency 
of applications, ease of use and treatment application time for amorol-
fine than for urea/bifonazole.
Difficulty to follow the procedure and concerns for tolerance were 
among the primary reasons for not following the urea/ bifonazole 
treatment procedure as per label. The complete ablation of softened 
diseased nail by the urea ointment was not effective for nearly half of 
treated nails after 2 weeks and required intervention by the investi-
gator after the third week for the removal of the residual nail plate in 
nearly 40% of treated nails.
Incomplete nail debridement following daily application of urea 
ointment for 2- 4 weeks is a determinant factor for efficacy and is 
therefore considered an exclusion criterion when studying the efficacy 
of bifonazole cream in onychomycosis.31 Although urea ointments are 
F IGURE  4 Subject questionnaire for Study A: (A) frequency of application, (B) ease of use and (C) overall satisfaction; and Study B: (D) 
frequency of application, (E) ease of use, (F) overall satisfaction and (G) local side effects
(A)
(D) (E)
(F) (G)
(B) (C)
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available OTC, the success rate of home debridement, without the 
support of a health professional, remains largely unexplored. Based on 
the available evidence, home debridement with urea ointment may be 
challenging, with reported failure to completely debride the affected 
nail area after 3 weeks ranging between 40%- 60%.26 A previous study 
on onychomycosis, comparing the efficacy of urea and bifonazole 
alone to that of the same local therapy combined with short- term oral 
griseofulvin, showed that the mean time to detachment of the dis-
eased nail was longer than the recommended 2- 3 weeks of treatment 
(24.9 days).32 The findings of Study B discussed in this article confirm 
the limitations of home treatment for complete nail debridement with 
urea ointment.
All three treatment regimens showed a favourable safety profile 
with no treatment- related AEs or AEs leading to discontinuation.
A shortcoming of these studies is the limited duration of treat-
ment for amorolfine and ciclopirox compared to their usual course of 
therapy (9- 12 months). Therefore, on this occasion, it was not possible 
to assess the impact of treatment efficacy and duration on subject 
adherence.
Collectively, the results of these two studies demonstrated that 
subjects found the once- weekly application of an antifungal nail lac-
quer with prior nail filing significantly easier to follow than chemical 
nail debridement. Fewer applications were missed with weekly ap-
plications of amorolfine nail lacquer than with daily applications of 
ciclopirox nail lacquer or bifonazole cream. Thus, the once- weekly 
administration of amorolfine nail lacquer may facilitate patient adher-
ence to treatment and improve patient satisfaction, which are import-
ant factors for efficacy with an OTC treatment.
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